UFA
UTHR icon

US Financial Advisors’s United Therapeutics UTHR Stock Holding History

US Financial Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-50
Closed -$8K – 606
2015
Q4 		$8K Buy
+50
New +$7.28K 0.01% 344

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

US Financial Advisors's UTHR Position: Q1 2016 in Review

US Financial Advisors sold out of United Therapeutics (UTHR) in Q1 2016, closing a stake of 50 shares — an estimated $8K sold.

US Financial Advisors first reported a position in UTHR in Q4 2015 and held it in 1 quarter. The position peaked at $8K in Q4 2015. 398 funds tracked by Wall St. Rank hold UTHR as of Q1 2016.

  • US Financial Advisors reported no remaining United Therapeutics position as of Q1 2016 after selling out during the quarter.
  • US Financial Advisors sold 50 United Therapeutics shares in Q1 2016, an estimated $8K.
  • US Financial Advisors first reported a position in United Therapeutics in Q4 2015 and held it in 1 quarter.
  • US Financial Advisors's United Therapeutics position peaked at $8K in Q4 2015.
  • 398 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2016.

Based on US Financial Advisors's 13F filing for Q1 2016, filed 5 May 2016.